Summary & Overview
HCPCS Q0235: Monoclonal Antibody Injection for Inpatient COVID-19 Treatment
HCPCS Level II code Q0235 denotes an injectable monoclonal antibody product for post-exposure prophylaxis or treatment of COVID-19 in hospitalized adults and pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The code is billed per 1 mg of product and applies specifically to the severe inpatient care setting, making it relevant to hospitals, critical care teams, and hospital billing operations. Nationally, the code matters because it captures high-acuity COVID-19 therapeutic use that can drive inpatient drug spend, resource allocation, and coding oversight.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical settings of use, guidance on payer coverage landscapes and common billing modifiers, and identification of operational considerations for hospital service lines. The publication highlights reimbursement and coding benchmarks where available and flags areas where data were not provided. This summary is intended for hospital administrators, revenue cycle and coding professionals, pharmacy directors, and clinical leaders involved in inpatient COVID-19 therapeutics and billing.
Billing Code Overview
HCPCS Level II code Q0235 describes an injection of monoclonal antibody products indicated for post-exposure prophylaxis or treatment of COVID-19 in hospitalized adult and pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The code is defined per 1 mg of product and is intended for use only in the severe inpatient setting described.
Service type: Monoclonal antibody injection for inpatient treatment or post-exposure prophylaxis of COVID-19
Typical site of service: Hospital inpatient (including intensive care units delivering supplemental oxygen, non-invasive ventilation, invasive mechanical ventilation, or ECMO).
Clinical & Coding Specifications
Clinical Context
A hospitalized adult with severe COVID-19 pneumonia who is receiving systemic corticosteroids and requires supplemental oxygen via high-flow nasal cannula is evaluated for adjunctive monoclonal antibody therapy. The patient is a candidate for inpatient administration of a monoclonal antibody indicated for treatment of COVID-19 in hospitalized patients receiving systemic corticosteroids and requiring supplemental oxygen. The clinical workflow includes: initial assessment by the inpatient team, review of indications and contraindications, informed consent documented in the chart, order entry for Q0235 including the calculated dose (per mg billing unit), verification of drug availability by pharmacy, preparation under sterile conditions by pharmacy or trained infusion staff, administration via intravenous injection or infusion with continuous monitoring for infusion reactions, documentation of drug name, lot number, dose (mg), route, start and stop times, and any adverse events. Post-administration monitoring is performed in the intensive care unit or step-down unit for patients on non-invasive or invasive ventilation, with nursing documentation of vital signs and oxygen/ventilatory support adjustments. Billing is submitted using HCPCS Level II code Q0235 with appropriate modifier(s) to reflect unusual circumstances, medical necessity, or payer-specific requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |